The price of targeted ovarian cancer drugs that entered the medical insurance market this year has been lowered again by about 80% compared to the initial listing price!

The new medical insurance prices in 2021 will be officially implemented across the country starting on March 1.

Take the targeted drug olaparib for the maintenance treatment of ovarian cancer as an example.

The strong medical insurance reimbursement has actually reduced the burden on patients.

"For patients with ovarian cancer, this is indeed good news!" Professor Wu Xiaohua, director of the Department of Gynecology, Chief Physician, and PhD supervisor of the Fudan University Affiliated Cancer Hospital, said frankly after understanding the price changes of olaparib in the new medical insurance catalog.

Professor Wu Xiaohua said that the importance of this targeted drug is that many ovarian cancers are genetically related.

Because of this, Professor Wu Xiaohua believes that the price reduction of olaparib into medical insurance will undoubtedly benefit patients with ovarian cancer.

It is precisely because of the continuous emergence of innovative methods for the treatment of tumors, including ovarian cancer, the survival period and quality of life of patients with tumors have been continuously improved.

Professor Wu Xiaohua said that for the treatment of ovarian cancer, because about 22% of patients carry BRCA1/2 mutations, the advent of the precise targeted drug PARP inhibitors for ovarian cancer has achieved a major breakthrough in the treatment of ovarian cancer.

While carrying out the full-course chronic disease management for patients who have been diagnosed or relapsed, Professor Wu Xiaohua also suggested that all newly diagnosed ovarian cancers need genetic testing including the BRCA gene.

Although ovarian cancer is a disease that harms and threatens women’s health and is also the disease with the highest mortality rate among all gynecological tumors, Professor Wu Xiaohua said that he is still confident to encourage ovarian cancer patients or their families.